Table 7.
LD 1 | LD 2 | LD 3 | LD 4 | LD 5 | LD 6 | LD 7 | LD 8 | n | ||
---|---|---|---|---|---|---|---|---|---|---|
Fasting glucose |
β | −0.018 | 0.005 | −0.003 | 0.003 | 0.004 | 0.016 | 0.012 | 0.002 | |
s.e. | 0.013 | 0.008 | 0.010 | 0.008 | 0.008 | 0.016 | 0.015 | 0.009 | 946 | |
p | 0.183 | 0.486 | 0.777 | 0.746 | 0.624 | 0.315 | 0.424 | 0.857 | ||
Fasting insulin |
β | 0.128 | 0.030 | 0.049 | 0.018 | 0.030 | 0.111 | 0.044 | 0.026 | |
s.e. | 0.042 | 0.025 | 0.030 | 0.025 | 0.027 | 0.052 | 0.046 | 0.029 | 946 | |
p | 0.002 | 0.214 | 0.104 | 0.468 | 0.269 | 0.033 | 0.349 | 0.371 | ||
HOMA-IR | β | 0.109 | 0.047 | 0.044 | 0.030 | 0.036 | 0.135 | 0.066 | 0.046 | |
s.e. | 0.046 | 0.027 | 0.033 | 0.0274 | 0.029 | 0.056 | 0.051 | 0.032 | 935 | |
p | 0.019 | 0.079 | 0.180 | 0.274 | 0.215 | 0.017 | 0.196 | 0.155 | ||
HbA1c | β | −0.005 | 0.001 | 0.001 | 0.001 | 0.001 | 0.002 | 0.001 | 0.008 | |
s.e. | 0.007 | 0.004 | 0.005 | 0.004 | 0.004 | 0.009 | 0.008 | 0.005 | 953 | |
p | 0.472 | 0.884 | 0.834 | 0.819 | 0.804 | 0.845 | 0.859 | 0.086 | ||
LDL-C | β | −0.031 | −0.034 | −0.021 | −0.044 | −0.032 | 0.016 | 0.021 | −0.041 | |
s.e. | 0.022 | 0.012 | 0.015 | 0.012 | 0.013 | 0.025 | 0.023 | 0.015 | 845 | |
P | 0.150 | 0.005 | 0.165 | 4.482 × 10−4 | 0.018 | 0.538 | 0.352 | 0.005 | ||
HDL-C | β | 0.010 | −0.006 | −0.001 | −0.017 | −0.016 | −0.028 | 0.021 | 0.010 | |
s.e. | 0.017 | 0.010 | 0.012 | 0.010 | 0.011 | 0.021 | 0.019 | 0.012 | 845 | |
p | 0.578 | 0.511 | 0.962 | 0.100 | 0.129 | 0.178 | 0.263 | 0.417 | ||
TG | β | 0.043 | −0.031 | 0.017 | −0.030 | −0.018 | 0.072 | 0.008 | −0.012 | |
s.e. | 0.038 | 0.021 | 0.026 | 0.022 | 0.023 | 0.045 | 0.040 | 0.026 | 845 | |
p | 0.260 | 0.142 | 0.517 | 0.169 | 0.427 | 0.107 | 0.833 | 0.642 | ||
γGT | β | 0.052 | -0.035 | −0.027 | −0.001 | −0.007 | 0.072 | −0.113 | −0.043 | |
s.e. | 0.048 | 0.028 | 0.035 | 0.029 | 0.030 | 0.059 | 0.053 | 0.034 | 958 | |
p | 0.287 | 0.205 | 0.429 | 0.965 | 0.828 | 0.224 | 0.034 | 0.198 | ||
AP | β | 0.014 | 0.022 | 0.009 | 0.020 | 0.014 | 0.020 | 0.003 | 0.018 | |
s.e. | 0.021 | 0.012 | 0.015 | 0.012 | 0.013 | 0.026 | 0.023 | 0.015 | 958 | |
p | 0.521 | 0.077 | 0.530 | 0.115 | 0.304 | 0.439 | 0.912 | 0.210 | ||
ALAT | β | 0.006 | −0.026 | −0.017 | −0.025 | −0.023 | 0.015 | −0.012 | −0.014 | |
s.e. | 0.030 | 0.017 | 0.021 | 0.017 | 0.019 | 0.036 | 0.033 | 0.021 | 958 | |
p | 0.850 | 0.133 | 0.425 | 0.145 | 0.217 | 0.685 | 0.724 | 0.508 | ||
ASAT | β | 0.020 | −0.020 | −0.006 | −0.022 | −0.013 | 0.007 | −0.003 | −0.016 | |
s.e. | 0.019 | 0.011 | 0.013 | 0.011 | 0.012 | 0.023 | 0.021 | 0.013 | 958 | |
p | 0.281 | 0.068 | 0.661 | 0.047 | 0.263 | 0.754 | 0.865 | 0.231 |
The presented associations were given for the representative SNP within each LD-group. Prior to analysis, all variables were ln-transformed except the covariate sex. p-values were adjusted for: sex, age, BMI and a p-value 0.05 was considered to be significant and was highlighted in bold. Linear regression including all subjects was conducted. For lipid parameters only subjects without lipid lowering medication were analyzed. LD = linkage disequilibrium; HOMA-IR = homeostasis assessment model of insulin resistance; HbA1c = hemoglobin A1c; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; TG = triglyceride; γGT = gamma-glutamyltransferase; AP = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; BMI = body-mass index; p = p-value; β = regression coefficient; s.e. = standard error; n = number of subjects.